BioGaia AB (publ) (ST:BIOG-B) — Market Cap & Net Worth
Market Cap & Net Worth: BioGaia AB (publ) (BIOG-B)
BioGaia AB (publ) (ST:BIOG-B) has a market capitalization of $1.15 Billion (Skr10.65 Billion) as of September 18, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #8322 globally and #128 in its home market, demonstrating a -1.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioGaia AB (publ)'s stock price Skr108.10 by its total outstanding shares 98497172 (98.50 Million). Also see BioGaia AB (publ) assets under control for a full breakdown of the balance sheet.
BioGaia AB (publ) Market Cap History: 2015 to 2026
BioGaia AB (publ)'s market capitalization history from 2015 to 2026. Data shows growth from $520.68 Million to $1.15 Billion (6.82% CAGR). Also see BIOG-B cash flow conversion for how efficiently the company converts equity into cash flow.
BioGaia AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioGaia AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check BioGaia AB (publ) stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.73x
BioGaia AB (publ)'s market cap is 0.73 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.38x
BioGaia AB (publ)'s market cap is 3.38 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $588.09 Million | $534.70 Million | $227.57 Million | 1.10x | 2.58x |
| 2017 | $644.81 Million | $615.00 Million | $180.56 Million | 1.05x | 3.57x |
| 2018 | $634.41 Million | $741.87 Million | $214.89 Million | 0.86x | 2.95x |
| 2019 | $856.04 Million | $768.35 Million | $187.35 Million | 1.11x | 4.57x |
| 2020 | $1.09 Billion | $747.08 Million | $179.73 Million | 1.46x | 6.07x |
| 2021 | $1.06 Billion | $785.11 Million | $196.27 Million | 1.35x | 5.40x |
| 2022 | $861.02 Million | $1.10 Billion | $373.77 Million | 0.78x | 2.30x |
| 2023 | $1.06 Billion | $1.30 Billion | $365.35 Million | 0.82x | 2.89x |
| 2024 | $1.19 Billion | $1.42 Billion | $351.39 Million | 0.83x | 3.38x |
| 2025 | $1.13 Billion | $1.54 Billion | $332.76 Million | 0.73x | 3.38x |
Competitor Companies of BIOG-B by Market Capitalization
Companies near BioGaia AB (publ) in the global market cap rankings as of September 18, 2026. Review tangible net worth ratio of BioGaia AB (publ) to assess the quality of the company's equity after excluding intangible assets.
Key companies related to BioGaia AB (publ) by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
BioGaia AB (publ) Historical Marketcap From 2015 to 2026
Between 2015 and today, BioGaia AB (publ)'s market cap moved from $520.68 Million to $ 1.15 Billion, with a yearly change of 6.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr1.15 Billion | +1.79% |
| 2025 | Skr1.13 Billion | -5.09% |
| 2024 | Skr1.19 Billion | +12.23% |
| 2023 | Skr1.06 Billion | +22.75% |
| 2022 | Skr861.02 Million | -18.79% |
| 2021 | Skr1.06 Billion | -2.83% |
| 2020 | Skr1.09 Billion | +27.47% |
| 2019 | Skr856.04 Million | +34.94% |
| 2018 | Skr634.41 Million | -1.61% |
| 2017 | Skr644.81 Million | +9.65% |
| 2016 | Skr588.09 Million | +12.95% |
| 2015 | Skr520.68 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of BioGaia AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.15 Billion USD |
| MoneyControl | $1.15 Billion USD |
| MarketWatch | $1.15 Billion USD |
| marketcap.company | $1.15 Billion USD |
| Reuters | $1.15 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioGaia AB (publ)
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well … Read more